Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group PLC (AIM:AVCT) Avacta to Present at Theranostics FAP Summit
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) Proposed acquisition of Launch Diagnostics
Launch Diagnostics is a leading independent distributor in the UK in-vitro diagnostics (IVD) market
Avacta Group PLC (AIM:AVCT) Phase I study of AVA6000 advances to fourth cohort
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AIM:AVCT) Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Avacta Group PLC (AIM:AVCT) AffyXell milestone and increased equity stake
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Avacta Group PLC (AIM:AVCT) Poster presented at the AACR available to download
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) AffyXell partners with Biocytogen and KNTSC
AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center